Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table 4–1 Vaccine Candidates

Vaccine

Target Population

Utilization (%)

Purchase $ (per dose)

Time to Licensure

Development $ (millions)

BORRELIA

 

 

Infants (restricted geography)

90

100

3

120

 

Migrants (restricted geography)

10

100

3

120

CHLAMYDIA

 

 

12-year-olds

50

50

15

360

COCCIDIOIDES IMMITIS

 

 

Infants (restricted geography)

90

50

15

360

 

Migrants (restricted geography)

10

50

15

360

CYTOMEGALOVIRUS

 

 

12-year-olds

50

50

7

360

ENTEROTOXIGENIC E. COLI

 

 

Infants

90

50

7

240

 

Travelers

30

50

7

240

EPSTEIN-BARR VIRUS

 

 

12-year-olds

50

50

15

390

HELICOBACTER PYLORI

 

 

Infants

30

50

7

240

HEPATITIS C

 

 

Infants

90

50

15

360

HERPES SIMPLEX VIRUS

 

 

12-year-olds

50

50

7

240

HISTOPLASMA CAPSULATUM

 

 

Infants (restricted geography)

90

50

15

360

 

Migrants (restricted geography)

10

50

15

360

HUMAN PAPILLOMA VIRUS

 

 

12-year-olds

50

100

7

360

INFLUENZA

 

 

Universal (every 5 years)

30

50

7

360

INSULIN-DEPENDENT DIABETES MELLITUS (therapeutic)

 

 

Early-stage patients

90

500

15

360



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement